We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BTSG's Specialty Pharmacy Sales Up 30%: Will the Growth Continue?
Read MoreHide Full Article
Key Takeaways
BrightSpring Health Services' Specialty and Infusion revenue grew 30% and scripts rose 31% in Q2 2026.
BrightSpring Health Services added two LDDs, bringing its portfolio to 155 programs, with 12 launched in 2026.
Pharmacy Solutions adjusted EBITDA rose 44% to $180 million, supported by branded LDDs and product mix.
BrightSpring Health Services’ (BTSG - Free Report) Specialty and Infusion business delivered another powerful quarter, with revenue increasing 30% year over year and scripts rising 31% in the second quarter. The performance reflects a combination of strong branded limited distribution drug (LDD) growth, new launches, fee-for-service programs, generics and acute-infusion expansion. Specialty Pharmacy remains anchored by the company’s branded oncology LDD portfolio, while management is increasingly extending its capabilities into rare, orphan and other complex therapies.
The LDD pipeline provides an important mechanism for sustaining this momentum. BTSG added two ultra-narrow-network LDDs during the quarter, bringing its total portfolio to 155 programs. Through the first half of 2026, the company launched 12 LDDs — four as exclusive partners and eight as ultra-narrow-network programs. Management views these launches as an important source of future growth because manufacturers increasingly require specialized infrastructure and patient-support capabilities to commercialize complex therapies.
Importantly, the opportunity is expanding beyond oncology. BTSG said it has several hundred clinical liaisons working across thousands of prescriber offices and 15 years of LDD experience, giving it an established commercial and clinical infrastructure that can be leveraged for rare and orphan therapies. Management described this market as smaller than oncology but still sizable enough to become a meaningful future contributor.
The financial contribution is already visible. Pharmacy Solutions’ adjusted EBITDA increased 44% to $180 million, with profitability benefiting from the strong branded LDD portfolio and favorable product mix. Management also expects continued quarter-over-quarter growth through the remainder of 2026.
Thus, BTSG’s 30% Specialty and Infusion growth appears supported by more than a single product cycle. A growing LDD portfolio, expansion into rare and orphan therapies, and established manufacturer-support capabilities could provide the runway needed to sustain above-market growth.
Peer Update
The Cigna Group’s (CI - Free Report) growth in the second quarter was increasingly driven by Specialty & Care, where pretax adjusted earnings rose 22% year over year to $1.1 billion. This was supported by continued specialty utilization growth, faster biosimilar adoption and greater penetration of specialty generics. Newer specialty generics achieved more than 80% penetration, improving operating efficiency and contributing favorably to earnings. Accredo’s differentiated specialty-pharmacy capabilities and the investment in Shields Health Solutions are also expanding Cigna’s reach into hospitals and health systems.
Management sees specialty pharmacy as a nearly $500 billion market with high-single-digit secular growth, providing substantial runway. While the second-quarter results benefited from generics and biosimilars, it is unlikely to repeat at the same magnitude. Management expects Specialty & Care to remain a meaningful earnings growth driver in the back half.
Humana’s (HUM - Free Report) second-quarter growth was driven primarily by Medicare Advantage (MA) membership, CenterWell expansion and operating improvements. Although the company has a presence in the Specialty market through its CenterWell Specialty Pharmacy portal, it did not specify its growth prospects separately. Management reported strong patient growth from organic expansion and acquisitions, while the company expects clinical excellence and operating efficiency to support meaningful MA margin expansion in 2027.
Pharmacy remains an important component of medical cost management — 2026 medical and pharmacy cost trends are expected at 7-8%, with Part D drug trends tracking in line with, or slightly better than expectations. Humana’s ability to manage members’ pharmacy and medical needs through value-based care, with better medication adherence and reduced hospitalization supporting broader medical economics, should help the company to drive growth.
BTSG’s Price Performance, Valuation and Estimates
Shares of BTSG have surged 65.5% year to date compared with the industry’s 1.8% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, BrightSpring Health Services trades at a forward price-to-earnings of 29.15X, above the industry average. It is also trading higher than its three-year median of 22.02X. BTSG carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for BrightSpring Health Services’ 2026 earnings implies an 82% rise from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Bigstock
BTSG's Specialty Pharmacy Sales Up 30%: Will the Growth Continue?
Key Takeaways
BrightSpring Health Services’ (BTSG - Free Report) Specialty and Infusion business delivered another powerful quarter, with revenue increasing 30% year over year and scripts rising 31% in the second quarter. The performance reflects a combination of strong branded limited distribution drug (LDD) growth, new launches, fee-for-service programs, generics and acute-infusion expansion. Specialty Pharmacy remains anchored by the company’s branded oncology LDD portfolio, while management is increasingly extending its capabilities into rare, orphan and other complex therapies.
The LDD pipeline provides an important mechanism for sustaining this momentum. BTSG added two ultra-narrow-network LDDs during the quarter, bringing its total portfolio to 155 programs. Through the first half of 2026, the company launched 12 LDDs — four as exclusive partners and eight as ultra-narrow-network programs. Management views these launches as an important source of future growth because manufacturers increasingly require specialized infrastructure and patient-support capabilities to commercialize complex therapies.
Importantly, the opportunity is expanding beyond oncology. BTSG said it has several hundred clinical liaisons working across thousands of prescriber offices and 15 years of LDD experience, giving it an established commercial and clinical infrastructure that can be leveraged for rare and orphan therapies. Management described this market as smaller than oncology but still sizable enough to become a meaningful future contributor.
The financial contribution is already visible. Pharmacy Solutions’ adjusted EBITDA increased 44% to $180 million, with profitability benefiting from the strong branded LDD portfolio and favorable product mix. Management also expects continued quarter-over-quarter growth through the remainder of 2026.
Thus, BTSG’s 30% Specialty and Infusion growth appears supported by more than a single product cycle. A growing LDD portfolio, expansion into rare and orphan therapies, and established manufacturer-support capabilities could provide the runway needed to sustain above-market growth.
Peer Update
The Cigna Group’s (CI - Free Report) growth in the second quarter was increasingly driven by Specialty & Care, where pretax adjusted earnings rose 22% year over year to $1.1 billion. This was supported by continued specialty utilization growth, faster biosimilar adoption and greater penetration of specialty generics. Newer specialty generics achieved more than 80% penetration, improving operating efficiency and contributing favorably to earnings. Accredo’s differentiated specialty-pharmacy capabilities and the investment in Shields Health Solutions are also expanding Cigna’s reach into hospitals and health systems.
Management sees specialty pharmacy as a nearly $500 billion market with high-single-digit secular growth, providing substantial runway. While the second-quarter results benefited from generics and biosimilars, it is unlikely to repeat at the same magnitude. Management expects Specialty & Care to remain a meaningful earnings growth driver in the back half.
Humana’s (HUM - Free Report) second-quarter growth was driven primarily by Medicare Advantage (MA) membership, CenterWell expansion and operating improvements. Although the company has a presence in the Specialty market through its CenterWell Specialty Pharmacy portal, it did not specify its growth prospects separately. Management reported strong patient growth from organic expansion and acquisitions, while the company expects clinical excellence and operating efficiency to support meaningful MA margin expansion in 2027.
Pharmacy remains an important component of medical cost management — 2026 medical and pharmacy cost trends are expected at 7-8%, with Part D drug trends tracking in line with, or slightly better than expectations. Humana’s ability to manage members’ pharmacy and medical needs through value-based care, with better medication adherence and reduced hospitalization supporting broader medical economics, should help the company to drive growth.
BTSG’s Price Performance, Valuation and Estimates
Shares of BTSG have surged 65.5% year to date compared with the industry’s 1.8% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, BrightSpring Health Services trades at a forward price-to-earnings of 29.15X, above the industry average. It is also trading higher than its three-year median of 22.02X. BTSG carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for BrightSpring Health Services’ 2026 earnings implies an 82% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The company currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.